Europe, despite excellent science, lost its co-equal status in drug development to the U.S. due to restrictive pricing and lack of growth capital. These same challenges are now emerging in the U.S., threatening its innovation leadership as China accelerates its efforts.

Rather than lamenting the distance from Silicon Valley, top European founders frame their location as an advantage. They become the undisputed top company for ambitious, loyal, and less-expensive talent in cities like Stockholm or Warsaw, attracting engineers eager for a generational opportunity.

A European founder targeting the US market shouldn't dismiss European VCs. You might be the top priority in a European firm's portfolio, receiving more attention and support than you would as a lower-priority deal for a top-tier, oversubscribed Silicon Valley firm.

Unlike tech investing, where a single power-law outlier can return the entire fund, biotech wins are smaller in magnitude. This dynamic forces biotech VCs to prioritize a higher success rate across their portfolio rather than solely hunting for one massive unicorn.

While a challenging fundraising market seems negative, it forces startups to operate with discipline. Unlike in frothy markets where companies expand based on hype, the current climate rewards tangible results. This compels a lean structure focused on high-value projects, creating a healthier long-term business model.

Recent billion-dollar successes in the French biotech ecosystem, such as Abivax and Medincel, are largely credited to their management teams. These leaders often have significant experience working in the US and other countries. This global perspective enables them to develop assets for a worldwide market, navigate different regulatory environments, and attract international funding, breaking the mold of previously localized French biotechs.

Denmark's leadership in biosolutions is not accidental. It's built on a unique ecosystem combining a cultural heritage in fermentation, patient capital from large foundations like Novo Nordisk, and a dense collaborative network connecting universities and companies of all sizes.

Beyond providing non-dilutive capital, the Flemish government's funding system (VLAIO) includes access to experts who actively challenge a startup's scientific proposals. This process forces strategic rigor and helps refine projects to be more translatable and robust. This built-in expert review is a key advantage of the Belgian biotech ecosystem, making companies smarter, not just richer.

Beyond a supportive ecosystem, CDR Life's CEO highlights Switzerland's dense concentration of well-trained life science professionals from big pharma, biotech, and top universities as its most critical advantage. This makes it easier to hire and retain the specialized talent essential for a biotech's success.